Fatiha Chermat

1.0k total citations
19 papers, 73 citations indexed

About

Fatiha Chermat is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Fatiha Chermat has authored 19 papers receiving a total of 73 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 10 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Fatiha Chermat's work include Acute Myeloid Leukemia Research (15 papers), Hemoglobinopathies and Related Disorders (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Fatiha Chermat is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Hemoglobinopathies and Related Disorders (6 papers) and Histone Deacetylase Inhibitors Research (5 papers). Fatiha Chermat collaborates with scholars based in France, Netherlands and Denmark. Fatiha Chermat's co-authors include Pierre Fenaux, Thomas Cluzeau, Sylvain Thépot, Lionel Adès, Pierre‐Yves Dumas, Rosa Sapena, Sophie Dimicoli‐Salazar, Richard van Wijk, Simone Boehrer and Éric Jourdan and has published in prestigious journals such as Blood, BMJ Open and Transfusion.

In The Last Decade

Fatiha Chermat

16 papers receiving 73 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fatiha Chermat France 5 53 20 20 15 10 19 73
Habib El‐Khoury United States 6 60 1.1× 32 1.6× 21 1.1× 28 1.9× 14 1.4× 17 102
Lenny Straszkowski Australia 4 33 0.6× 22 1.1× 17 0.8× 18 1.2× 3 0.3× 8 66
Anitria Cotton United States 3 30 0.6× 22 1.1× 26 1.3× 13 0.9× 7 0.7× 7 65
Nobuo Sezaki Japan 7 48 0.9× 23 1.1× 18 0.9× 11 0.7× 34 3.4× 13 104
Craig A. Kovitz United States 4 87 1.6× 20 1.0× 74 3.7× 26 1.7× 7 0.7× 13 131
Florence Rabian France 7 44 0.8× 12 0.6× 12 0.6× 34 2.3× 12 1.2× 17 78
Kristin L Koenig United States 4 57 1.1× 40 2.0× 23 1.1× 24 1.6× 18 1.8× 13 98
Asif Alavi United States 6 41 0.8× 26 1.3× 17 0.8× 17 1.1× 11 1.1× 14 74
Vladimir Ivanov Russia 6 38 0.7× 17 0.8× 12 0.6× 14 0.9× 9 0.9× 16 82
Sergey Voloshin Russia 5 43 0.8× 25 1.3× 27 1.4× 27 1.8× 4 0.4× 50 87

Countries citing papers authored by Fatiha Chermat

Since Specialization
Citations

This map shows the geographic impact of Fatiha Chermat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatiha Chermat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatiha Chermat more than expected).

Fields of papers citing papers by Fatiha Chermat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatiha Chermat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatiha Chermat. The network helps show where Fatiha Chermat may publish in the future.

Co-authorship network of co-authors of Fatiha Chermat

This figure shows the co-authorship network connecting the top 25 collaborators of Fatiha Chermat. A scholar is included among the top collaborators of Fatiha Chermat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatiha Chermat. Fatiha Chermat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Adès, Lionel, Thomas Cluzeau, Thibault Comont, et al.. (2024). Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study. Blood. 144(Supplement 1). 351–351. 3 indexed citations
2.
3.
4.
5.
6.
Beers, Eduard J. van, Richard van Wijk, Minke A.E. Rab, et al.. (2023). Safety and Efficacy of Mitapivat in Adult Patients with Erythrocyte Membranopathies (SATISFY). Blood. 142(Supplement 1). 1085–1085. 1 indexed citations
7.
Bris, Yannick Le, Pascal Turlure, Patrice Chevallier, et al.. (2022). Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351. Blood. 140(Supplement 1). 9821–9823. 1 indexed citations
8.
Cony‐Makhoul, Pascale, Jean‐François Hamel, Sylvain Thépot, et al.. (2022). Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM). Transfusion. 62(5). 961–973. 6 indexed citations
9.
Conrads‐Frank, Annette, Ursula Rochau, Karin A. Koinig, et al.. (2021). Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists. Blood Advances. 6(1). 1–12. 4 indexed citations
10.
Péterlin, Pierre, Pascal Turlure, Patrice Chevallier, et al.. (2021). CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. Blood. 138(Supplement 1). 243–243. 13 indexed citations
11.
Rabian, Florence, Jérôme Lambert, Daniela Barbieri, et al.. (2020). Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study. Blood. 136(Supplement 1). 15–16. 2 indexed citations
12.
Cony‐Makhoul, Pascale, Sylvain Thépot, Thomas Cluzeau, et al.. (2020). Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM). Blood. 136(Supplement 1). 42–43. 2 indexed citations
13.
Kubasch, Anne Sophie, Katharina S. Götze, Jan Krönke, et al.. (2018). Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. Blood. 132(Supplement 1). 4045–4045. 14 indexed citations
14.
Sébert, Marie, Aspasia Stamatoullas, Thorsten Braun, et al.. (2015). Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM). Blood. 126(23). 2884–2884. 2 indexed citations
15.
Thépot, Sylvain, Simone Boehrer, Thomas Prébet, et al.. (2014). A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia Research. 38(12). 1430–1434. 13 indexed citations
16.
17.
Prébet, Thomas, Thorsten Braun, Odile Beyne‐Rauzy, et al.. (2012). Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure. Blood. 120(21). 3825–3825. 2 indexed citations
18.
Prébet, Thomas, Thorsten Braun, Odile Beyne Rauzy, et al.. (2010). A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study. Blood. 116(21). 4003–4003. 2 indexed citations
19.
Fabre, Claire, Enrique Hernández, Fatiha Chermat, et al.. (2007). P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program. Leukemia Research. 31. S122–S122.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Habib El‐Khoury Breakdown of academic impact, for papers by Lenny Straszkowski Breakdown of academic impact, for papers by Anitria Cotton Breakdown of academic impact, for papers by Nobuo Sezaki Breakdown of academic impact, for papers by Craig A. Kovitz Breakdown of academic impact, for papers by Florence Rabian Breakdown of academic impact, for papers by Kristin L Koenig Breakdown of academic impact, for papers by Asif Alavi Breakdown of academic impact, for papers by Vladimir Ivanov Breakdown of academic impact, for papers by Sergey Voloshin
Rankless by CCL
2026